Tag Archives: SCHOTT Pharma Confirms 2026 Outlook Following Resilient First-Half Results and Expansion Investments

SCHOTT Pharma Reports Solid H1 2026 Performance Driven by Strong Demand for Specialized Injectable Solutions

(IN BRIEF) SCHOTT Pharma delivered a resilient performance during the first half of fiscal year 2026, reporting revenue growth despite ongoing market challenges and maintaining strong profitability. The company benefited from continued demand for high-value pharmaceutical containment products, especially sterile … Read the full press release